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ARTICLE
Bone-targeting AAV-mediated silencing of
Schnurri-3 prevents bone loss in osteoporosis
Yeon-Suk Yang1,6, Jun Xie 2,3,4,6, Dan Wang 2,3, Jung-Min Kim1, Phillip W.L. Tai 2,3, Ellen Gravallese1,
Guangping Gao 2,3,4,5 & Jae-Hyuck Shim1,5
RNAi-based bone anabolic gene therapy has demonstrated initial success, but many practical
challenges are still unmet. Here, we demonstrate that a recombinant adeno-associated virus
9 (rAAV9) is highly effective for transducing osteoblast lineage cells in the bone. The adaptor
protein Schnurri-3 (SHN3) is a promising therapeutic target for osteoporosis, as deletion of
shn3 prevents bone loss in osteoporotic mice and short-term inhibition of shn3 in adult mice
increases bone mass. Accordingly, systemic and direct joint administration of an rAAV9
vector carrying an artiﬁcial-microRNA that targets shn3 (rAAV9-amiR-shn3) in mice markedly
enhanced bone formation via augmented osteoblast activity. Additionally, systemic delivery
of rAAV9-amiR-shn3 in osteoporotic mice counteracted bone loss and enhanced bone
mechanical properties. Finally, we rationally designed a capsid that exhibits improved spe-
ciﬁcity to bone by grafting the bone-targeting peptide motif (AspSerSer)6 onto the AAV9-
VP2 capsid protein. Collectively, our results identify a bone-targeting rAAV-mediated gene
therapy for osteoporosis.
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Adult bone mass is determined by the balance betweenbone formation by osteoblasts and bone resorption byosteoclasts. Disturbances in this equilibrium to favor
osteoclast-mediated resorption result in low bone density and
deterioration of bone structure, which increase the risk of frac-
tures1. Current leading osteoporosis therapies target osteoclasts to
inhibit bone resorption, but these therapeutic agents are accom-
panied by numerous side effects, including atypical femoral
fractures and osteonecrosis of the jaw2. Only two anabolic agents,
parathyroid hormone3 and parathyroid hormone-related pro-
tein4,5, exist for promoting osteoblast function to treat patients
with osteoporosis. However, these agents are costly, require fre-
quent injections, and have the potential for promoting the
development of osteosarcomas. Recently developed agents
including the antisclerostin antibody6 and a small molecule
inhibitor of Cathepsin K7 can increase bone mass and reduce
fracture risk in osteoporosis. However, these drugs show adverse
cardiovascular events in clinical trials8. Thus, therapeutic agents
that can treat osteoporosis without adverse effects are still an
unmet need.
We previously identiﬁed the adaptor protein Schnurri-3
(SHN3) as a potent endogenous inhibitor of bone forma-
tion9,10. Mice lacking shn3 in osteoblasts display a signiﬁcant
increase in bone mass. The SHN3 zinc-ﬁnger protein is encoded
by the Hivep3 gene in humans and mice, and is herein referred to
as shn3. It controls osteoblast differentiation by promoting
RUNX2 degradation9 and suppressing the Wnt signaling pathway
by inhibiting ERK MAPK activity11. In addition, SHN3 inhibits
the production of the proangiogenic factor SLIT3, which supports
the CD31highendomucinhigh vascular endothelium during bone
formation10. Lastly, SHN3 deﬁciency is not associated with any
observable phenotypes in nonskeletal tissues10,12. These proper-
ties together make SHN3 inhibition an attractive approach to
promote bone formation to treat osteoporosis.
Adeno-associated virus (AAV) is a small (26 nm) none-
nveloped parvovirus with a single-stranded genome of ~4.7 kb in
length13. High transduction efﬁciency, persistent transgene
expression, and lack of post-infection immunogenicity and
pathogenicity make AAV an attractive viral vector for use in gene
therapy14. The AAV genome encodes regulatory proteins (Rep)
and structural capsid proteins (Cap) and is ﬂanked by two
inverted terminal repeats. Replacement of the Rep and Cap genes
with a transgene of interest produces a replication-defective
recombinant AAV (rAAV) genome that can transduce target
tissues as a potent vector15,16. Second-generation self-com-
plementary AAVs (scAAVs) that package a double-stranded
DNA genome were engineered to bypass the rate-limiting sec-
ond-strand synthesis step required for rAAV transgene expres-
sion17–20. As a result, scAAV vectors have enhanced transduction
efﬁcacies in vitro and in vivo. To date, AAV vectors have
been evaluated in over 130 clinical trials worldwide21. However,
AAV-based gene therapies for bone and joint disorders are
limited22.
In this study, we demonstrate that among 14 conventional
serotypes tested23, AAV9 is the most effective for in vitro and
in vivo transduction of osteoblast lineage cells. Similar to bone
accrual by tamoxifen-induced deletion of shn3 in osteoblasts,
systemic delivery of an rAAV9 packaged with a Cre recombinase
transgene in mice harboring a ﬂoxed shn3 allele can efﬁciently
mediate shn3 deletion in osteoblasts to increase bone accrual.
Importantly, we provide a proof-of-concept demonstration that
an rAAV vector that carries an artiﬁcial microRNA (amiR) tar-
geting shn3 can reverse bone loss and enhance bone quality in a
mouse model of osteoporosis. Finally, to improve osteo-speciﬁc
transduction, the bone-targeting peptide motif (AspSerSer)624
was grafted onto the AAV9-VP2 capsid protein, resulting in
signiﬁcant reduction of transgene expression in nonbone per-
ipheral organs.
Results
Transduction of AAV serotypes in bone and cartilage. We ﬁrst
aimed to identify the best AAV serotype for transducing cells of
the bone and cartilage lineage in vitro. An scAAV vector con-
struct expressing the enhanced green ﬂuorescent protein
(Egfp) reporter gene was packaged into 14 conventional AAV
capsids (AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV6.2,
AAV7, AAV8, AAV9, AAVrh.8, AAVrh.10, AAVrh.39, and
AAVrh.43)25 and incubated with mouse calvarial osteoblasts
(COBs), bone marrow-derived osteoclast precursors (BM-OCPs),
and chondrocyte progenitor cells (ATDC5s) at three different
MOIs. Expression of EGFP in transduced cells was assessed by
immunoblotting with an anti-EGFP antibody (Fig. 1a, b) and
ﬂuorescence microscopy (Supplementary Fig. 1). Eight AAV
serotype vectors, rAAV1, rAAV4, rAAV5, rAAV6, rAAV7,
rAAV9, rAAVrh10, and rAAVrh39 were able to transduce COBs
(Fig. 1a). Among these, rAAV1, rAAV4, rAAV5, rAAV6, rAAV7,
and rAAV9 also transduced BM-OCPs, while rAAV1, rAAV6,
rAAVrh.10, and rAAVrh.39 transduced ATDC5 cells. Interest-
ingly, rAAV2 and rAAV6.2 transduced ATDC5 cells efﬁciently,
but poorly in COBs.
We note that the transduction efﬁciencies of rAAVs in vitro are
scarcely predictive of their in vivo performance. This phenom-
enon is due to the presence of multiple physiological barriers,
including the route of administration, serum factors, circulating
neutralizing antibodies, and extracellular barriers25. Therefore,
in vivo evaluation to assess the ability of serotypes to transduce-
speciﬁc tissues or cell types is required. To examine the tropism of
AAV capsids to articular cartilage and bone, eight rAAV-Egfp
vectors selected from the in vitro screen (rAAV1, rAAV4, rAAV5,
rAAV6, rAAV7, rAAV9, rAAVrh.10, and rAAVrh.39) were
intraarticularly (i.a.) injected into knee joints of 2-month-old
mice, and EGFP expression was monitored by IVIS-100 optical
imaging of whole bone (Fig. 1c) and by ﬂuorescence microscopy
of bone cryosections (Fig. 1d–f and Supplementary Fig. 2).
Surprisingly, there was little to no expression of EGFP in the
growth plate (Fig. 1d) or the articular cartilage (Supplementary
Fig. 2a) for the majority of capsids. This discrepancy may be due
to the poor accessibility of rAAV vectors to chondrocytes, which
are embedded in the avascular microenvironment of these
structures. Alternatively, vectors may simply exhibit a lower
infectivity of primary chondrocytes in adult mice. While most
rAAV vectors showed relatively higher EGFP expression in the
adjacent muscle (Supplementary Fig. 2b), EGFP expression in
trabecular and cortical bone was only detected in rAAV9-treated
hindlimbs (Fig. 1d, e and Supplementary Fig. 2b). Speciﬁcally,
rAAV9-mediated EGFP expression in the femur was detected in
osteoblasts and osteoclasts on the bone surface, and in osteocytes
embedded in the bone matrix (Supplementary Fig. 2c). Notably,
EGFP expression was also detected in a subset of Osteocalcin- or
Runx2-positive osteoblasts, Cathepsin K-positive osteoclasts, and
Sclerostin-positive osteocytes, demonstrating the ability of AAV9
to transduce osteoblasts, osteoclasts, and osteocytes in vivo
(Fig. 1f).
Systemic delivery of rAAV9 can target osteoblasts. To test
AAV9’s ability to target bone tissue in vivo when delivered sys-
temically, rAAV9-Egfp was injected into 2-month-old mice and
the tissue distribution of rAAV9 was assessed by EGFP expres-
sion 2 weeks post injection. Whole body and individual organ
imaging of treated mice showed that EGFP expression was the
highest in the liver and hindlimbs (Fig. 2a and Supplementary
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Fig. 1 Identiﬁcation of rAAV vectors that transduce bone cells in vitro and in vivo. a, b Calvarial osteoblasts (COB), bone marrow-derived osteoclast
precursors (BM-OCP), or chondrogenic cells (ATDC5), were treated with PBS or 14 different AAV capsids packaged with the same CB-Egfp transgene.
After 2 days, EGFP expression was assessed by immunoblotting with an anti-GFP antibody (a). The anti-Hsp90 antibody was used as a loading control.
b Immunoblot quantiﬁcation of EGFP protein was measured as a percentage of endogenous Hsp90 protein level by ImageJ software. c–f A single dose of
1 × 1011 genome copies of rAAV was intraarticularly (i.a.) injected into the knee joints of 2-month-old male mice, and EGFP expression in the hindlimb was
monitored by IVIS-100 optical imaging 2 weeks post injection (c). Femurs were cryosectioned and EGFP expression was assessed by ﬂuorescence
microscopy (d). e High-magniﬁcation images of EGFP-expressing cells in the femur. Cryo-sectioned femurs were also immunostained for Bglap, Runx2,
Ctsk, and Sost to identify osteoblasts, mature osteoclasts, and osteocytes, respectively (f). TB, trabecular bone; BM, bone marrow; GP, growth plate; CB,
cortical bone. Scale bars: d 500 μm; e 100 μm; f 25 μm
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Fig. 2 Inducible deletion of shn3 in osteoblasts increases bone accrual in adult mice. a–d A single dose of 4 × 1011 genome copies of rAAV9-Egfp was
intravenously (i.v.) injected into 2-month-old male mice and EGFP expression in individual tissues was monitored by IVIS-100 optical imaging 2 weeks post
injection. y-axis, radiant efﬁciency (p/s/cm2/sr/μW/cm2) (a). EGFP expression was assessed by ﬂuorescence microscopy on cryo-sectioned heart, liver
(b), and femur (c). A high-magniﬁcation image of EGFP-expressing osteoblasts in the femur (c, right). Immunoblot of tissue lysates with an anti-GFP
antibody (d). e–g Two-month-old female Ocn-Ert;RosamT/mG and Shn3Ocn-Ert;RosamT/mG mice were treated with 100mg/kg of tamoxifen for 5 consecutive
days; 2 months later, femurs were cryo sectioned to identify EGFP-expressing osteoblasts (e). Femoral trabecular bone mass was assessed by microCT.
Representative 3D reconstruction (f) and relative quantiﬁcation (g) are displayed. Trabecular bone volume/total volume (Tb. BV/TV), trabecular thickness
(Tb.Th), trabecular number per cubic millimeter (Tb.N), and trabecular space (Tb. Sp) (n= 6 per group). h–k A single dose of 4 × 1011 genome copies of
rAAV9-Egfp or rAAV9-Cre was i.v. injected into 3-month-old male Shn3ﬂ/ﬂ;RosamTmG mice. After 2 months, cre and shn3 mRNA levels were assessed in
tibial bone RNA and normalized to hprt (h). Fluorescence microscopy was performed on cryo-sectioned femurs to identify EGFP-expressing cells (i) and
femoral trabecular bone mass was assessed by microCT. Representative 3D reconstruction (j) and relative quantiﬁcation (k) are displayed. Trabecular
bone volume/total volume (Tb. BV/TV), trabecular thickness (Tb. Th), trabecular number per cubic millimeter (Tb. N), and connective density (Conn. Dn)
(n= 6 per group). Scale bars: b 50 μm; c 500 μm (left), 75 μm (right); e 25 μm; f, j 1 mm; i 250 μm. Values represent mean ± SD: *P < 0.05; **P < 0.01; and
***P < 0.001 by an unpaired two-tailed Student’s t-test (g, h, k)
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Fig. 3a, b). Expression in the heart and femur was modest, while
expression in the lung, kidney, and spleen was not detected.
Expression of EGFP in the heart, liver, femur, and vertebrae was
further conﬁrmed by ﬂuorescence microscopy (Fig. 2b, c and
Supplementary Fig. 3c, d) and immunoblot analysis (Fig. 2d). As
observed in i.a. injected hindlimbs, EGFP protein was primarily
expressed in endosteal osteoblasts and osteocytes in cortical and
trabecular bones, but not in the ligament, articular cartilage,
growth plate, periosteal osteoblasts, and patella (Fig. 2c and
Supplementary Fig. 4). These results demonstrate that systemi-
cally delivered rAAV9 vector targets osteoblast lineage cells
residing in the endosteal bone.
shn3 deletion promotes bone formation in adult mice. Our
previous studies identiﬁed SHN3 as a potent suppressor of
osteoblast differentiation9,11,12. Speciﬁcally, conditional deletion
of a ﬂoxed shn3 allele with Cre-deleter mice targeting mesench-
ymal stem cells (Shn3Prx1)12 or mature osteoblasts/osteocytes
(Shn3Dmp1)10 results in a signiﬁcant increase in bone accrual. To
examine the effects of short-term inhibition of SHN3 on bone
formation, we generated an inducible, osteoblast-speciﬁc shn3-
knockout mice by crossing Shn3ﬂ/ﬂ mice with osteocalcin-CreERT
mice expressing a tamoxifen-induced Cre recombinase in mature
osteoblasts26 (Shn3Ocn-Ert). These mice were further crossed with
the Cre-reporter RosamT/mG mice to visualize Cre-expressing
cells27 (Shn3Ocn-Ert; RosamT/mG). Treatment of Shn3Ocn-Ert;
RosamT/mG mice with tamoxifen resulted in the expression of
GFP in mature osteoblasts on the surface of trabecular and cor-
tical bones, indicating osteoblast-speciﬁc deletion of shn3
(Fig. 2e). Accordingly, these mice showed a signiﬁcant increase in
trabecular bone mass and a mild increase in cortical bone
thickness compared to tamoxifen-treated control mice (Fig. 2f, g
and Supplementary Fig. 5). These results demonstrate that
inducible deletion of Shn3 in mature osteoblasts is sufﬁcient to
increase bone mass in adult mice.
To provide proof-of-concept demonstration that systemically
delivered rAAV9 can direct the deletion of snh3 in osteoblast
lineage cells to promote bone formation, we generated a Cre-
encoding rAAV9 vector (rAAV9-Cre, Supplementary Fig. 6a) to
serve as the facilitator for Cre-recombination in Shn3ﬂ/ﬂ mice. We
ﬁrst treated rAAV9-Cre in cultured COBs isolated from Shn3ﬂ/ﬂ
mice (Supplementary Fig. 6b), and as expected, rAAV9-mediated
Cre expression in Shn3ﬂ/ﬂ COBs resulted in the deletion of shn3
and enhanced osteoblast differentiation (Supplementary
Fig. 6c–e). We next injected rAAV9-Cre into 2-month-old
Shn3ﬂ/ﬂ;RosamT/mG mice via i.v. administration. Two months
after injection, expression of Cre mRNA in the femur (Fig. 2h,
left) and Cre-mediated expression of EGFP protein in osteoblast
lineage cells residing on the bone surface (Fig. 2i) were validated
by RT-PCR and ﬂuorescence microscopy, respectively. Compared
to rAAV9-Egfp-treated femurs, rAAV9-Cre-treated femurs
showed a signiﬁcant decrease in shn3 mRNA levels (Fig. 2h,
right) and an increase in relative trabecular bone mass in the
femur and lumbar vertebrae (Fig. 2j, k and Supplementary
Fig. 7a). However, cortical bone at the femoral diaphysis showed
no signiﬁcant change in thickness (Supplementary Fig. 7b). These
results demonstrate that systemically delivered rAAV9-Cre in
Shn3ﬂ/ﬂ mice targets osteoblast lineage cells and mediates shn3
deletion to increase bone mass. Importantly, our results
demonstrate that rAAV9-mediated transgene delivery to osteo-
blast lineage cells can dramatically alter bone physiology.
rAAV9-mediated silencing of shn3 promotes bone formation.
High levels of AAV-delivered shRNAs can induce cytotoxicity by
perturbing the RNAi machinery or exhibit signiﬁcant off-target
silencing28,29. Embedding the guide strand of a small silencing
RNA into the mouse miR-33-derived miRNA scaffold limits
shRNA-related toxicity and enables efﬁcient gene knockdown,
while reducing off-target silencing by tenfold compared to con-
ventional shRNA constructs30. We therefore engineered amiR
cassettes to target shn3 (amiR-shn3) or a control (amiR-ctrl). In
this design, the amiR is inserted intronically between the CB
promoter and the Egfp reporter gene (Fig. 3a), which allows for
visual tracking of positively transduced cells or tissues. First, we
validated gene knockdown efﬁcacy of the amiR cassettes by
transfecting Myc-tagged mouse shn3 into HEK293 cells along
with plasmids encoding amiR-shn3 or amiR-ctrl plasmids (Sup-
plementary Fig. 8a). Constructs were then packaged into AAV9
capsids. Treatment with rAAV9-amiR-shn3 or rAAV9-amiR-ctrl
resulted in positively transduce COBs in vitro (Supplementary
Fig. 8b). Compared to amiR-ctrl-treated COBs, treatment with
rAAV9-amiR-shn3 resulted in ~50% reduction of shn3 mRNA
levels, and relative increases in ibsp expression and mineralization
(Supplementary Fig. 8c, d).
To examine the ability of rAAV9-amiR-shn3 to enhance bone-
anabolic activity in vivo, vector was injected via i.a. administra-
tion into knee joints of 2-month-old mice. Two months following
treatment, EGFP expression in hindlimbs and femurs was
examined by IVIS optical imaging (Fig. 3b) and ﬂuorescence
microscopy (Fig. 3c), respectively. Importantly, FACS-sorted
EGFP-expressing cells isolated from the femur showed ~50%
reduction of shn3 mRNA levels (Fig. 3d). Compared to amiR-ctrl-
treated femurs, amiR-shn3-treated femurs showed a signiﬁcant
increase in relative trabecular bone mass (Fig. 3e, f). These results
demonstrate that local delivery of rAAV9-amiR-shn3 is effective
in knocking down SHN3 expression in osteoblast lineage cells,
and in turn, increases bone mass in vivo.
We next tested whether rAAV9-amiR-shn3 could promote
in vivo bone-anabolic activity following systemic delivery. Two
months after i.v. administration into 3-month-old mice, EGFP
expression was predominantly detected in the hindlimbs, liver,
and heart as expected (Supplementary Fig. 9a–c). Femurs
transduced by rAAV9-amiR-shn3 displayed ~50% reduction of
shn3 mRNA levels (Fig. 3g) and a signiﬁcant increase in
trabecular bone mass of the femur and lumbar vertebrae (Fig. 3h,
i and Supplementary Fig. 9d). No signiﬁcant change in cortical
bone thickness at the femoral diaphysis between treatment groups
was observed (Supplementary Fig. 9e). Likewise, in vivo osteo-
blast activity was increased in the trabecular bone in the
metaphysis of these mice, as shown by the greater bone formation
rate (BFR), mineral apposition rate (MAR), and osteoblast surface
per bone surface (Ob.S/BS) of rAAV9-amiR-shn3-treated mice
(Fig. 3j, k). However, the number of tartrate-resistant acid
phosphatase (TRAP)-positive osteoclasts and serum levels of the
bone resorption marker C-terminal telopeptide type I collagen
(CTX) were unchanged in these mice (Supplementary Fig. 9f, g).
These results demonstrate that systemic delivery of rAAV9-amiR-
shn3 reduced shn3 expression in osteoblast lineage cells,
augmented osteoblast activity, and increased bone mass without
any alteration in osteoclast number and function in vivo. Thus,
the rAAV9-amiR-shn3 vector may be useful for the treatment of
osteoporosis as a potent bone anabolic agent.
Effects of rAAV9-mediated silencing of Shn3 in osteoporosis.
Inhibition of WNT antagonists has been recognized as a new
approach for therapeutic intervention in patients with osteo-
porosis6. Our previous studies identiﬁed SHN3 as an inhibitor of
osteoblast differentiation via perturbation of Wnt signaling9,11,12.
Ovariectomized (OVX) mice serve as established models for
estrogen deﬁciency-induced osteoporosis31. To further establish
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Fig. 3 Silencing of SHN3 by systemically delivered rAAV9 promotes bone formation. a Diagram of the rAAV9 construct containing a CMV enhancer/
chicken β-actin promoter (CB), amiR-ctrl or amiR-shn3, an Egfp reporter gene (EGFP), β-globin polyA sequence (PA), and inverted terminal repeat (ITR).
b–d Two weeks after i.a. injection of rAAV9 carrying amiR-ctrl or amiR-shn3 into knee joints of 2-month-old male mice, EGFP expression was assessed by
IVIS-100 optical imaging (b) and ﬂuorescence microscopy of cryo-sectioned femurs (c). Levels of EGFP protein (d, top) and shn3 mRNAs normalized to
hprt (d, bottom) were assessed in FACS-sorted EGFP-expressing cells from the femur. e, f Two months after i.a. injection of rAAV9 carrying amiR-ctrl or
amiR-shn3 into knee joints of 2-month-old female mice, femoral trabecular bone mass was assessed by microCT. Representative 3D reconstruction (e) and
relative quantiﬁcation (f) are displayed (n= 6 per group). g–k A single dose of 4 × 1011 genome copies of rAAV9 carrying amiR-ctrl or amiR-shn3 were i.v.
injected into 3-month-old female mice. After 2 months, shn3 mRNA levels were assessed in the tibial bone RNA and normalized to hprt (g, n= 8 per
group). Femoral trabecular bone mass was assessed by microCT. Representative 3D reconstruction (h) and relative quantiﬁcation (i) are displayed (n= 8
per group). Representative calcein/alizarin red labeling (j) and relative histomorphometric quantiﬁcation of BFR/BS, MAR, and Ob.S/BS are displayed (k).
Arrows indicate the distance between calcein and alizarin red labeling. BFR/BS, bone formation rate/bone surface; MAR, mineral apposition rate; Ob.S/BS,
osteoblast surface/bone surface. GP, growth plate; BM, bone marrow; TB, trabecular bone. Scale bars: c 250 μm; e, h 1 mm; j 50 μm. Values represent
mean ± SD: **P < 0.01; ***P < 0.001; and ****P < 0.0001 by an unpaired two-tailed Student’s t-test (f, g, i, k)
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that inhibition of SHN3 may be an attractive target to promote
bone formation as a therapy for osteoporosis, 3-month-old female
mice lacking SHN3 (Shn3−/−) were subjected to ovariectomies,
and bone mass was assessed by microCT 2 months post surgery.
While OVX surgery induced a signiﬁcant reduction in trabecular
bone mass in WT mice, OVX-induced bone loss was completely
prevented by shn3 deletion, as trabecular bone mass was com-
parable between sham-Shn3−/− mice and OVX-Shn3−/− mice
(Fig. 4a, b). Thus, targeting shn3 may have therapeutic potential
to prevent bone loss in osteoporosis.
To test the therapeutic effects of rAAV9-amiR-shn3 in
osteoporosis, sham or OVX surgery was conducted on 3-
month-old wild-type female mice, and vector was i.v. injected
6 weeks post surgery (Fig. 4c). After 7 weeks, treated femurs
showed efﬁcient transduction, leading to ~50% knockdown of
shn3 (Fig. 4d, e). As expected, amiR-ctrl-expressing OVX mice
showed a signiﬁcant decrease in trabecular bone mass in the
femur and lumbar vertebrae relative to sham mice (Fig. 4f, g and
Supplementary Fig. 10a, b). However, when treated with rAAV9-
amiR-shn3, bone loss was completely reversed in the femur and
lumbar vertebrae of OVX mice, as shown by greater trabecular
BV/TV, thickness, and connectivity density. No signiﬁcant
change in cortical bone thickness at the diaphysis between all
three groups was observed (Supplementary Fig. 10c). Likewise,
femoral BFR and MAR were increased in these mice relative to
amiR-ctrl-expressing OVX mice, demonstrating enhanced osteo-
blast activity in vivo (Fig. 4h, i). Notably, shn3 silencing by
rAAV9-amiR-shn3 does not alter osteoclast function in vivo as
the number of TRAP-positive osteoclasts and bone resorption
activity are comparable between OVX mice expressing amiR-ctrl
and amiR-shn3 (Supplementary Fig. 10d, e). Finally, biomecha-
nical testing showed that the strength and stiffness of femurs were
considerably protected from OVX-induced bone loss of mice
treated with rAAV9-amiR-shn3 (Fig. 4j), suggesting that rAAV9-
mediated silencing of shn3 improves clinically meaningful
endpoints in osteoporotic mice. Taken together, these results
demonstrate that systemically delivered rAAV9-amiR-shn3 pro-
motes bone formation and enhances clinically relevant mechan-
ical properties of bone after the onset of OVX-induced
osteoporosis.
Generation of a novel bone-tropic capsid of rAAV9. As
demonstrated above, the majority of rAAV9 targets nonbone
peripheral tissues, limiting the speciﬁcity of the rAAV9-amiR-
shn3 if delivered systemically. Since newly developed agents for
osteoporosis, such as antisclerostin antibody (Romosozumab)
and the small molecule inhibitor of Cathepsin K (Odanacatib)
show off-target cardiovascular and cerebrovascular events in
clinical trials8,32, a bone-speciﬁc treatment strategy must be
developed. Thus, we aimed to detarget transduction from
nonrelevant tissues by modifying the AAV9 capsid through a
rational design approach to avoid potential nonskeletal side
effects of rAAV9-mediated gene therapy. A previous study
reported that the bone-targeting peptide motif, ((AspSerSer)6,
DSS) was effective in directing an osteogenic siRNA-
encapsulated liposome to the bone-forming surface, where
osteoblast lineage cells typically reside24. Thus, to improve the
ability of rAAV9 to target osteoblast lineage cells, DSS-
encoding DNA sequences were inserted into either of two
capsid positions that are amendable to peptide grafting33, at the
loop IV domain between glutamine 587 and alanine 588
(AAV9.DSS-588) or at the N-terminus of VP2 (AAV9.DSS-
Nter) (Fig. 5a). To test whether DSS insertion affects produc-
tion of rAAV9, genome titers (GCs) of vectors packaged into
prototypical AAV9, AAV9.DSS-588, or AAV9.DSS-Nter
capsids were assessed by droplet digital PCR (ddPCR),
demonstrating ~50% reduction in AAV9.DSS-588 or AAV9.
DSS-Nter GCs compared to wild-type AAV9 GCs (Supple-
mentary Fig. 11a). Next, vectors were infected into COBs, and
EGFP expression was assessed by immunoblotting (Fig. 5b) or
ﬂuorescence microscopy (Fig. 5c, left). Compared to rAAV9,
the rAAV9.DSS-Nter showed a modest reduction of infectivity
at lower MOI (109 GC/mL), whereas little EGFP expression was
detected in COBs treated with rAAV9.DSS-588 (Fig. 5b, c, left).
Similarly, when treating mice via i.a. injections, rAAV9 and
rAAV9.DSS-Nter strongly transduced femurs as before (Sup-
plementary Fig. 11b). In contrast, the rAAV9.DSS-588 yielded
little to no transgene expression. In addition, treating COBs and
BM-OCPs with rAAV9 and rAAV9.DSS vectors did not sig-
niﬁcantly alter respective osteoblast or osteoclast differentiation
markers (Fig. 5c, right and Supplementary Fig. 11c–g), sug-
gesting that treatment with rAAV9s does not lead to any
vector-related adverse effects.
Since the AAV9.DSS-Nter engineered capsid still retained full
transduction activity in vitro, we next tested the capsid for bone-
targeting activity in vivo. As before, rAAV9-Egfp or rAAV9.DSS-
Nter-Egfp vectors were i.v. injected into 2-month-old mice and
their tissue distributions were assessed by EGFP expression
2 weeks post injection. Mice treated with rAAV9.DSS-Nter
yielded EGFP expression levels in nonbone tissues that were
comparatively less than those treated with rAAV9 (almost no
expression in the heart, ~55% reduction in the liver, and ~75%
reduction in the hindlimb) (Fig. 5d and Supplementary Fig. 12a,
b). These results were supported by immunoblot and ﬂuorescence
microscopy data, which showed a lack of detectable EGFP in the
heart, and a signiﬁcant reduction in the liver and muscle among
the rAAV9.DSS-Nter injection groups (Fig. 5e, f and Supple-
mentary Fig. 12c). Importantly, expression in femurs and lumbar
vertebrae were relatively comparable between treatment groups
(Fig. 5e–g and Supplementary Fig. 12d). Similar to rAAV9-
treated femurs, EGFP expression in rAAV9.DSS-Nter-treated
femurs was detected in a subset of Runx2-positive osteoblasts,
Cathepsin K-positive osteoclasts, and Sclerostin-positive osteo-
cytes (Supplementary Fig. 12e). Intriguingly, the number of
EGFP-expressing cells on the bone surface in rAAV9.DSS-Nter-
treated femurs was increased relative to those in rAAV9-treated
femurs when EGFP-expressing bone marrow cells were excluded
for quantiﬁcation (Fig. 5h). These results demonstrate that the
engineered VP2 capsid protein fused with the bone-targeting
peptide motif (DSS) improves the bone tropism of rAAV9 in part
by detargeting delivery to nonskeletal tissues.
We next examined the capacity for the AAV9.DSS-Nter bone-
tropic capsid to deliver the therapeutic amiR-shn3 transgene
(rAAV9.DSS-Nter-amiR-shn3) to OVX mice. Sham or OVX
surgery was conducted on 3-month-old female mice and rAAV9.
DSS-Nter-amiR-shn3 was i.v. injected 6 weeks post surgery. Seven
weeks after injection, animals exhibited strong EGFP expression
in the liver, hindlimbs, and tails (Supplementary Fig. 13a), and in
osteoblast lineage cells of femurs (Supplementary Fig. 13b),
indicating robust transduction. Levels of shn3 mRNAs were
markedly reduced in amiR-shn3-expressing OVX femurs relative
to amiR-ctrl-expressing sham or OVX femurs (Fig. 5i). While
amiR-ctrl-expressing OVX mice showed a signiﬁcant reduction in
trabecular bone mass of femurs and lumbar vertebrae relative to
sham mice, bone loss among OVX mice treated with rAAV9.
DSS-Nter-amiR-shn3 was signiﬁcantly reversed (Fig. 5j–m and
Supplementary Fig. 13c). No signiﬁcant change in cortical bone
thickness at the diaphysis between all three groups was observed
(Supplementary Fig. 13d). Taken together, these results demon-
strate that delivery of amiR-shn3 by the bone-tropic AAV9.DSS-
Nter capsid can counteract bone loss in osteoporosis.
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Fig. 4 rAAV9-mediated silencing of shn3 prevents bone loss in a mouse model of osteoporosis. a, b Sham or OVX surgery was performed on 3-month-old
female Shn3+/+ and Shn3−/− mice and 2 months later, femoral trabecular bone mass was assessed by microCT. Representative images of the femur (a)
and relative BV/TV (b) are displayed (n= 6 per group). c–j Diagram of the study and treatment methods (c). Sham or OVX surgery was performed on 3-
month-old female mice and 6 weeks later, a single dose of 4 × 1011 genome copies of rAAV9 carrying amiR-ctrl or amiR-shn3 was i.v. injected. Seven weeks
after injection, femurs were cryo sectioned to identify EGFP-expressing cells (d). shn3 mRNA levels in tibial bone are displayed after normalization to hprt
(n= 8–12 per group) (e). Femoral trabecular bone mass was assessed by microCT. Representative 3D reconstruction (f) and relative quantiﬁcation (g) are
displayed (n= 7–8 per group). Representative images of calcein/alizarin red labeling (h) and relative histomorphometric quantiﬁcation of BFR/BS and
MAR (i). Arrows indicate the distance between calcein and alizarin red labeling. Femoral biomechanical properties, including bending rigidity, bending
moment, apparent bending modulus, and apparent bending stress were quantiﬁed (n= 5–9 per group) (j). Scale bars: a, f 1 mm; d 250 μm; and h 50 μm.
Values represent mean ± SD: N.S., not signiﬁcant; *P < 0.05; **P < 0.01; ***P < 0.001; and ****P < 0.0001 by an unpaired two-tailed Student’s t-test (b) and
one-way ANOVA test (e, g, i, j)
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Discussion
Due to their lack of pathogenicity, AAV vectors have a long
track record for safety and efﬁcacy in relevant preclinical and
clinical studies34. In addition, AAV vectors are capable of
persisting in post-mitotic cells of host tissues for years35,36. For
instance, a nonhuman primate study demonstrated that ani-
mals treated with a single-dose, intramuscular administration
of an rAAV-Epo vector exhibited transgene persistence after
more than 6 years37. In contrast, nonviral vectors such as
nanoparticles and liposomes can be rapidly degraded, cleared in
the circulation, have short biological half-lives, and generally
exhibit nonspeciﬁc uptake38. In this study, we have demon-
strated that rAAV9 serotype can target osteoblast lineage cells
to drive RNAi-mediated silencing of shn3, which we show has a
clinical signiﬁcance as a genetic target to prevent bone loss and
osteoporosis. Importantly, we now describe a promising
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platform for rAAV-based gene therapy for bone. Nonetheless,
the long-term therapeutic outcomes of rAAV-mediated gene
silencing in treating osteoporosis requires further investigation.
rAAV9-mediated gene therapy is currently the leading plat-
form for treating neurological disorders39, in part, due to
rAAV9’s ability to traverse the blood–brain barrier to target the
central nervous system (CNS) when administered i.v.40. In
addition, rAAV9 has been shown to transduce various peripheral
tissues systemically, such as liver, retina, and striated muscles in
adult mice41,42. Despite previous studies showing that in utero
and calvarial administration of rAAV9 can transduce bone tissue
in fetal and neonatal mice41,43, its ability to transduce cells within
the adult bone tissue has gone largely unexplored. To our
knowledge, this study is the ﬁrst demonstration that systemic
delivery of rAAV9 to adult mice can transduce osteoblasts,
osteocytes, and osteoclasts in bone, while articular cartilage,
growth plate, and ligament, and bone marrow are relatively
refractory to rAAV9 transduction.
SHN3 is a promising therapeutic target for osteoporosis, evi-
dent by our ﬁndings that, (1) deletion of shn3 completely prevents
bone loss in a mouse model for osteoporosis and (2) short-term
inhibition of SHN3 in adult mice increases bone formation. In
addition, our proof-of-concept study demonstrated that a sys-
temically delivered rAAV9.amiR-shn3 vector can promote bone
formation to fully reverse bone loss and enhance bone mechanical
properties in osteoporosis, suggesting that rAAV9-mediated
silencing of shn3 improves clinically meaningful endpoints.
While RNAi-based strategies to promote bone formation as
therapies have been described before, such drugs in the form of
bone anabolic liposomes24 or lipid-based nanoparticles44 require
repeated injections. We demonstrate that a single systemic
injection of rAAV9-amiR-shn3 is sufﬁcient to increase bone
accrual in mice.
Our study was partially guided by previous investigations that
examined the therapeutic potential for anti-sclerostin antibodies6
to increase bone mass and to reduce fracture risk due to osteo-
porosis. Related clinical trials unfortunately showed off-target
cardiovascular adverse effects32. Here, our data conﬁrm that
rAAV9 can extensively transduce nonbone tissues, including
cardiac muscle at low levels (Fig. 2a, b). It was therefore apparent
that potential cardiovascular adverse effects of rAAV9 in the
heart and other nonbone organs be considered. In addition, the
engineering of improved capsids and vectors for bone-speciﬁc
gene therapy is fundamentally important, despite extensive clin-
ical successes for rAAV9, and our results suggesting that systemic
knockdown of shn3 using rAAV9 only impacts bone formation.
Our platform, which utilizes an amiR approach, has yet to be fully
tested in relevant preclinical models. As such, we do not fully
understand the extent of safety and efﬁcacy in human patients.
These concerns are especially critical considering that AAV9 can
target a wide range of tissues and has the capacity to cross the
blood–brain barrier to target the CNS. To address this downside
to AAV9, we engineered a capsid by grafting the bone-targeting
peptide motif onto AA9-VP2. This rationally designed capsid,
named AAV9.DSS-Nter, exhibits remarkable reduced tropism to
liver, heart, and muscle. Since the DSS peptide motif has a higher
binding afﬁnity to the osteoblast-enriched bone-formation sur-
face than to the osteoclast-enriched bone-resorption surface24,
display of the DSS peptide on the capsid protein may enhance
rAAV9’s ability to transduce osteoblast lineage cells in vivo.
Systemic delivery of amiR-shn3 or other therapeutic transgenes
via rAAV9.DSS-Nter may have clinical utility for counteracting
bone loss in other human diseases, such as inﬂammatory
arthritis-induced bone loss. In addition, local delivery of ther-
apeutic transgenes via rAAV9.DSS-Nter to areas of bone fracture
may also be useful for enhancing bone healing. This possibility
opens the door to future work that explores the therapeutic effects
of rAAV-mediated gene therapy in the bone. We note that
rAAV9-mediated silencing of shn3 is more effective to increase
trabecular bone mass at the metaphysis than cortical bone
thickness at the femoral diaphysis. This outcome is likely due to
relatively lower bone remodeling activity of cortical bone at the
diaphysis. Future vector improvements to transduce exclusively
osteoblast lineage cells such as using osteoblast-speciﬁc promoters
in the AAV vector genome design or the further improvements to
capsids will allow for even more precise bone-targeting rAAV
vectors that can deliver therapeutic genes absent of any non-
skeletal effects.
Methods
rAAV vector design and production. The artiﬁcial miRNA against mouse shn3
gene was designed by using a custom Excel macro, which considers miR-33 scaf-
fold design rules to generate optimized amiR cassettes. The tool will be shared upon
request. Plasmids were constructed by Gibson assembly and standard molecular
biology methods. DNA sequences for amiR-33-ctrl and amiR-33-shn3 were syn-
thesized as gBlocks and cloned into the intronic region of the pAAVsc-CB6-Egfp
plasmid at the restriction enzyme sites (PstI and BglII)45. The pAAVsc-CB6-Cre
was generated by replacing the Egfp reporter with Cre recombinase. Constructs
were veriﬁed by sequencing. Our previous study showed that doxycycline-inducible
expression of shRNA targeting mouse shn3 in transgenic mice resulted in a
decrease in shn3 mRNA levels and a relative increase in bone mass11. The same
targeting sequence was used to generate the amiR-33-shn3 cassette. The pAAV-
amiR-ctrl and pAAV-amiR-shn3 constructs were packaged into AAV9 capsids. In
addition, the pAAVsc-CB6-Egfp construct was packaged into AAV1 (1.8E+ 13
GC/ml), AAV2 (1.5E+ 12 GC/ml), AAV3 (6E+ 12 GC/ml), AAV4 (6.5E+ 12
GC/ml), AAV5 (2.4E+ 13 GC/ml), AAV6 (8E+ 12 GC/ml), AAV6.2 (8E+ 12
GC/ml), AAV7 (1.5E+ 13 GC/ml), AAV8 (7E+ 12 GC/ml), AAV9 (1.5E+ 13
GC/ml), AAVrh8 (8E+ 12 GC/ml), AAVrh10 (8E+ 12 GC/ml), AAVrh39 (1.0E
+ 13 GC/ml), and AAVrh43 (6E+ 12 GC/ml) capsids. rAAV production was
performed by transient transfection of HEK293 cells, puriﬁed by CsCl sedi-
mentation, titered by ddPCR on a QX200 ddPCR system (Bio-Rad) using the Egfp
prime/probe set as previously described46. The sequences of gBlocks and oligo-
nucleotides for ddPCRare listed in Supplementary Table 1.
Fig. 5 Effect of rAAV9.DSS-Nter-amiR-shn3 in a mouse model of osteoporosis. a Diagram of constructs for rationally designed bone-speciﬁc AAV capsids.
The bone-targeting peptide motif (DSS, red) was inserted into the AAV9 capsid between Q588 and A589 (DSS-588) or at the N-terminus of AAV9-VP2
(DSS-Nter). cap: capsid proteins. b, c Two days after infection with different concentrations of rAAV9, rAAV9.DSS-588, or rAAV9.DSS-Nter, COBs were
cultured under osteogenic conditions for 6 days. EGFP expression was assessed by immunoblotting with an anti-GFP antibody (b) or ﬂuorescence
microscopy (c, left). ALP activity was assessed by fast blue staining (c, right). d–h A single dose of 4 × 1011 genome copies of rAAV9 or rAAV9.DSS-Nter
was i.v. injected into 2-month-old male mice. EGFP expression in individual tissues was monitored by IVIS-100 optical imaging 2 weeks post injection (d).
Immunoblotting shows EGFP expression in tissue lysates (e) and relative quantiﬁcation (f, n= 3 per group). Fluorescence microscopy was performed on
cryo-sectioned femurs to identify EGFP-expressing cells (g) and the number of EGFP-expressing cells per bone surface in femurs were quantiﬁed (h, n= 5
per group). i–m Sham or OVX surgery was performed on 3-month-old female mice. After 6 weeks, a single dose of 4 × 1011 genome copies of rAAV9.DSS-
Nter carrying amiR-ctrl or amiR-shn3 was i.v. injected. Seven weeks after injection, shn3 mRNA levels were assessed in the tibial bone (i, n= 10 per group).
Trabecular bone mass in the femur and lumbar vertebrae was assessed by microCT. Quantiﬁcation (j, m) and representative 3D reconstruction (k, l) are
displayed (n= 6 ~ 8 per group). GP, growth plate; BM, bone marrow; TB, trabecular bone. Scale bars: g 100 μm; c, k, i 1 mm. Values represent mean ± SD:
N.S., not signiﬁcant; *P < 0.05; **P < 0.01; ***P < 0.001; and ****P < 0.0001 by an unpaired two-tailed Student’s t-test (f, h) and one-way ANOVA test (i, j,m)
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Generation of bone-targeting rAAV9 vector. The DNA sequence encoding the
bone-targeting peptide motif DSS (AspSerSer)6 was codon-optimized. To generate
the Q588-DSS-A589 capsid (DSS-588), a plasmid expressing AAV2 rep gene and
AAV9 cap gene (pAAV2/9) was modiﬁed to insert the DSS sequence into the
AAV9 cap gene between the Q588 and A589 codons (pAAV2/9.Q588-DSS-A589).
This plasmid was used in rAAV production (5–8E+ 12 GC/ml). To generate the
DSS-Nter capsid, we used a pair of plasmids. First, the start codon of VP2 in
pAAV2/9 was mutated (ACG→ACC), so that only VP1 and VP3 are expressed
(pAAV2/9.noVP2). In another plasmid, the DSS sequence was fused to the N-
terminus of the AAV9-VP2 ORF. A Kozak sequence and ATG start codon were
placed immediately upstream of the DSS sequence allowing for optimal expression
driven by the CMV promoter [pcDNA.DSS-VP2(AAV9)]. The plasmids pAAV2/9.
noVP2 and pcDNA.DSS-VP2(AAV9) were used in rAAV production (6–10E+ 12
GC/ml).
Cells. The chondrogenic ATDC5 cells were purchased from Sigma and cultured in
DMEM/Ham’s F12 medium supplemented with 2% FBS, 2 mM L-glutamine and
1% penicillin/streptomycin. In addition, primary osteoprogenitors (COB) were
isolated from calvaria of 5-day-old wild-type neonates (C57BL/6 J) using Col-
lagenase type II (50 mg/ml, Worthington, LS004176) and Dispase II (100 mg/ml,
Roche, 10165859001) and were maintained in α-MEM medium (Gibco) containing
10% FBS (Gibco), 2 mM L-glutamine (Corning), 1% penicillin/streptomycin
(Corning), and 1% nonessential amino acids (Corning). COBs were differentiated
with ascorbic acid (200 uM, Sigma, A8960) and β-glycerophosphate (10 mM,
Sigma, G9422). Finally, bone marrow cells were ﬂushed from the femurs and tibias
of 2-month-old mice (C57BL/6 J), and cultured in petri dishes in α-MEM medium
with 10% FBS and 20 ng/ml of M-CSF (R&D systems) to obtain bone BM-OCP.
After 12 h, nonadherent cells were replated into tissue culture dishes and cultured
in the same medium for 3 days. BM-OCPs then differentiated into osteoclasts in
the presence of RAMKL (20 ng/ml; R&D systems) and M-CSF (20 ng/ml; R&D
systems) for 6 days.
Mice. Shn3−/− mice9 and Shn3ﬂ/ﬂ mice47 were generated as previously described
and maintained on BALB/cJ and C57BL/6J background, respectively. Osteocalcin-
ERT/Cre mice with tamoxifen-induced Cre recombinase expression in mature
osteoblasts48 were crossed with Shn3ﬂ/ﬂ mice to obtain Shn3ﬂ/ﬂ;Ocn-ERT/Cre mice
(C57BL/6J). To label Cre-expressing cells, Shn3ﬂ/ﬂ;Ocn-ERT/Cre mice were further
crossed with RosamT/mG cre reporter mice (C57BL/6J)27. For postnatal activation of
ERT/Cre, 100 mg/kg tamoxifen (Sigma) in corn oil (Sigma) was intraperitoneally
injected to 2-month-old female mice once a day for 5 consecutive days.
Mouse genotypes were determined by PCR on tail genomic DNA. Primer
sequences are available upon request. Control littermates were used and analyzed
in all experiments. The animal protocols were reviewed and approved by the
University of Massachusetts Medical School on animal care (IACUC), and were
conformed to the NIH Guide for the Care and Use of Laboratory Animals.
MicroCT analysis. MicroCT was used for qualitative and quantitative assessment
of trabecular and cortical bone microarchitecture and performed by an investigator
blinded to the genotypes of the animals under analysis. Femurs excised from the
indicated mice were ﬁxed with 10% neutral buffered formalin and scanned using a
microCT 35 (Scanco Medical) with a spatial resolution of 7 μm. For trabecular
bone analysis of the distal femur, an upper 2.1 mm region beginning 280 μm
proximal to the growth plate was contoured. For cortical bone analysis of femur, a
mid-shaft region of 0.6 mm in length was used. MicroCT scans of L4 spinal seg-
ments were performed using isotropic voxel sizes of 12 μm. Three-dimensional
reconstruction images were obtained from contoured two-dimensional images by
methods based on distance transformation of the binarized images. Alternatively,
the Inveon multimodality 3D visualization program was used to generate fused 3D
viewing of multiple static or dynamic volumes of microCT modalities (Siemens
Medical Solutions USA, Inc). All images presented are representative of the
respective genotypes (n > 5).
Histology, histomorphometry, and immunoﬂuorescence. For histological ana-
lysis, femurs and vertebrae were dissected from the mice treated with rAAVs
vectors, ﬁxed in 10% neutral buffered formalin for 2 days, and decalciﬁed by 5%
tetrasodium EDTA for 2–4 weeks. Tissues were dehydrated by passage through an
ethanol series, cleared twice in xylene, embedded in parafﬁn, and sectioned at a
thickness of 6 μm along the coronal plate from anterior to posterior. Decalciﬁed
femoral sections were stained with hematoxylin and eosin (H&E) or TRAP.
For dynamic histomorphometric analysis, 25 mg/kg calcein (Sigma, C0875) and
50 mg/kg alizarin-3-methyliminodiacetic acid (Sigma, A3882) dissolved in 2%
sodium bicarbonate solution were subcutaneously injected into mice at 6 days
interval. After ﬁxed in 10% neutral buffered formalin for two days, undecalciﬁed
femur samples were embedded in methylmethacrylate and proximal metaphysis is
sectioned longitudinally (5 μm) and stained with McNeal’s trichrome for osteoid
assessment, toluidine blue for osteoblasts, and TRAP for osteoclasts49. A region of
interest is deﬁned in the trabecular bone in the metaphysis and BFR/bone surface
(BS), MAR, BS, Ob.S/BS, and osteoclast surface (Oc.S/BS) are measured using a
Nikon Optiphot 2 microscope interfaced to a semiautomatic analysis system
(Osteometrics). Measurements were taken on two sections/sample (separated by
~25 μm) and summed prior to normalization to obtain a single measure/sample in
accordance with ASBMR standards50. This methodology has undergone extensive
quality control and validation and the results were assessed by two different
researchers in a blinded fashion.
For immunoﬂuorescence, fresh femurs and vertebrae dissected from rAAV-
treated mice were collected and immediately ﬁxed in ice-cold 4%
paraformaldehyde solution for 2 days. Semidecalciﬁcation was carried out for
5 days in 0.5 M EDTA pH 7.4 at 4 °C with constant shaking (age ≥ 1 week), and
inﬁltration was followed with a mixture of 20% sucrose phosphate buffer for 1 day
and with 25% sucrose phosphate buffer next day. All samples were embedded in
50/50 mixture of 25% sucrose solution and OCT compound (Sakura) and cut into
12-μm-thick sagittal sections using a cryostat (Leica). Immunoﬂuorescence staining
and analysis was performed as described previously49,51. Brieﬂy, after treatment
with 0.2% Triton X-100 for 10 min, sections were blocked with 5% donkey serum
at room temperature for 30 min and incubated overnight at 4 °C with anti-BGLAP
antibody (sc-365797, Santa Cruz, 1:150). Primary antibodies were visualized with
donkey anti-rat IgG Alexa-594 (1:500, Molecular Probes). Nuclei were
counterstained with 4-6,diamidino-2-phenylindole (DAPI). An Olympus IX81
confocal microscope or Leica TCS SP5 II Zeiss LSM-880 confocal microscope was
used to image samples.
Biomechanical analysis. Femora were mechanically tested in three-point bending
using an electrical force mechanical testing machine (Electroforce 3230, Bose
Corporation, Eden Prairie, MN) at the Center for Skeletal Research Imaging and
Biomechanical Testing Core. The bending ﬁxture had a bottom span length of 8
mm. The test was performed with the load point in displacement control moving at
a rate of 0.05 mm/s with force and displacement data collected at 60 Hz. All of the
bones were positioned in the same orientation during testing with the cranial
surface resting on the supports and being loaded in tension. Bending rigidity (EI,
N-mm2), apparent modulus of elasticity (Eapp, MPa), ultimate moment (Mult, N-
mm), apparent ultimate stress (σapp, MPa), work to fracture (Wfrac, mJ), and
apparent toughness (Uapp, mJ/mm3) were calculated based on the force and dis-
placement data from the tests and the mid-shaft geometry measured with
microCT. Work to fracture is the energy that was required to cause the femur to
fracture, and it was calculated by ﬁnding the area under the force–displacement
curve using the Riemann Sum method. Bending rigidity was calculated using the
linear portion of the force–displacement curve. The minimum moment of inertia
was used when calculating the apparent modulus of elasticity.
ELISA analysis. CTX1 ELISA (Abclonal MC0850) analysis was performed by
using a kit according to the manufacturer’s instructions.
Osteoblast differentiation analysis. For alkaline phosphatase (ALP) staining,
osteoblasts were ﬁxed with 10% neutral formalin buffer and stained with the
solution containing Fast Blue (Sigma, FBS25) and Naphthol AS-MX (Sigma, 855).
Alternatively, osteoblasts were incubated with tenfold diluted Alamar Blue solution
(Invitrogen, DAL1100) for cell proliferation. Subsequently, cells were washed and
incubated with a solution containing 6.5 mM Na2CO3, 18.5 mM NaHCO3, 2 mM
MgCl2, and phosphatase substrate (Sigma, S0942), and ALP activity was measured
by luminometer (Biorad).
To assess extracellular matrix mineralization in mature osteoblasts, cells were
washed twice with phosphate-buffered saline (PBS) and ﬁxed in 70% EtOH for 15
min at room temperature. Fixed cells were washed twice with distilled water and
then stained with a 2% alizarin red solution (Sigma, A5533) for 5 min. Cells were
then washed three times with distilled water and examined for the presence of
calcium deposits. Mineralization was quantiﬁed by the acetic acid extraction
method52.
Quantitative RT-PCR analysis. Total RNA was puriﬁed from cells using QIAzol
(QIAGEN) and cDNA was synthesized using the High-Capacity cDNA Reverse
Transcription Kit from Applied Biosystems. Quantitative RT-PCR was performed
using SYBR® Green PCR Master Mix (Bio-Rad) with CFX connect RT-PCR
detection system (Bio-Rad). To measure shn3 mRNA levels in bone tissues, after
removal of bone marrow, tibias were snap-frozen in liquid nitrogen for 30 s and in
turn homogenized in 1 ml of QIAzol for 1 min.
Alternatively, femurs and tibias dissected from rAAV9-treated mice were
crushed in Hanks Balanced Salt Solution (Life Technologies) containing 10 mM
HEPES (pH 7.2) (CellGro) and enzymatically digested with 2.5 mg/mL Collagenase
A (Roche) and 1 unit/mL Dispase II (Roche) for 15 min at 37 °C under gentle
agitation. The resulting cell suspensions were ﬁltered (40 µm), washed using PBS
(pH 7.2) containing 0.5% BSA (Fraction V) and 2 mM EDTA. After washing, cells
were resuspended in PBS (pH 7.2) with 2 mM EDTA and 1 µg/mL DAPI (live/dead
exclusion) and EGFP-expressing cells were sorted using a FACS Aria II SORP cell
sorter (Becton Dickinson) at the University of Massachusetts Medical School with
exclusion of DAPI+ cells and doublets. Total RNA was puriﬁed from cells using
QIAzol. Primers used for PCR are described in the Supplementary Table 1.
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Immunoblotting analysis. Cells were lysed in TNT lysis buffer (50 mM Tris-HCl
(pH 7.4), 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 50 mM
NaF, 1 mM Na3VO4, 1 mM PMSF, and protease inhibitor cocktail (Sigma)) and
protein amounts from cell lysates were measured using the DC protein assay (Bio-
Rad). Equivalent amounts of proteins were subjected to SDS-PAGE, transferred to
Immunobilon-P membranes (Millipore), immunoblotted with anti-GFP antibody
(JL-8, 632381, Takara, 1:1000), anti-Cre recombinase antibody (ab24607, Abcam,
1:1000), anti-Hsp90 antibody (675402, Biolegend, 1:1000), and developed with ECL
(Thermo ﬁsher scientiﬁc). Immunoblotting with anti-HSP90 antibody was used as
a loading control. Alternatively, dissected femurs and soft tissues were homo-
genized in RIPA lysis buffer (89900, Thermo ﬁsher scientiﬁc) and tissue lysates
were subjected to immunoblotting analysis.
In vitro transduction assay of rAAV serotypes. ATDC5 cells or primary COBs
were plated at a density of 1 × 104 cells/well in 24-well plate and 24 h later, they
were incubated with rAAV1, rAAV2, rAAV3, rAAV4, rAAV5, rAAV6, rAAV6.2,
rAAV7, rAAV8, rAAV9, rAAVrh8, rAAVrh10, rAAVrh39, or rAAVrh43 vectors
packaging the CB-Egfp reporter transgene at three different titers (109–1011/mL
genome copies). After 48 h, cells were washed with PBS and EGFP expression was
monitored by the EVOS FL imaging system (Thermo ﬁsher scientiﬁc). Alter-
natively, cells were lysed in TNT lysis buffer and EGFP expression was assessed by
immunoblotting with anti-EGFP antibody and quantiﬁed using ImageJ software.
(http://rsbweb,nih,gov/ij/). Lastly, primary bone marrow monocytes were plated at
a density of 5 × 105 cells/well in 24-well plates and cultured in the presence of 10
ng/ml of RAMKL and 20 ng/ml of M-CSF for 2 days to differentiate to osteoclast
precursors. Three days after treatment with rAAV-Egfp vectors, EGFP expression
was assessed by EVOS FL imaging system and by immunoblotting with anti-EGFP
antibody.
For screening rAAV vectors in vivo, 10 μl of rAAV-Egfp vectors (1 × 1011 GC;
5 × 1012 GC/kg) was i.a. injected into knee joints of 2-month-old male mice
(Jackson Laboratory, C57BL/6 J and BALB/cJ). Two weeks after injection, femurs
and knee joints were dissected for IVIS-100 optical imaging or cryo-sectioning.
rAAV9-mediated delivery of Cre recombinase or amiR-shn3. For a local
delivery, 10 μl of rAAV9 carrying amiR-ctrl or amiR-shn3 (1 × 1011 GC; 5 × 1012
GC/kg) was i.a. injected into knee joints of 2-month-old male mice (Jackson
Laboratory, C57BL/6 J). Two months after injection, femurs were dissected for
microCT analysis.
For a systemic delivery, 200 μl of rAAV9 carrying Egfp, Cre, amiR-ctrl, or amiR-
shn3 (4 × 1011 GC; 2 × 1013 GC/kg) was i.v. injected into mice (Jackson Laboratory,
C57BL/6J) and 2 months later, mice were subcutaneously injected with calcein and
alizarin-3-methyliminodiacetic acid at 6-day interval for dynamic
histomorphometric analysis. Nonlabeled mice were used to monitor EGFP
expression using the IVIS-100 optical imaging or cryosections.
Effects of rAAV9-mediated silencing of shn3 in osteoporosis. Mouse models of
postmenopausal osteoporosis were generated by anesthetizing and bilaterally OVX
3-month-old female mice (Jackson Laboratory, C57BL/6J). Six weeks after the
surgery, sham or OVX mice were i.v. injected with 200 μl of rAAV9 or rAAV9.
DSS-Nter carrying amiR-ctrl or amiR-shn3 (4 × 1011 GC; 2 × 1013 GC/kg). Mice
were randomly divided into six groups with rAAV9 or rAAV9.DSS-Nter: sham+
rAAV9-amiR-ctrl, OVX+ rAAV9-amiR-ctrl, OVX+ rAAV9-amiR-shn3, sham+
rAAV9.DSS-Nter-amiR-ctrl, OVX+ rAAV9.DSS-Nter-amiR-ctrl, OVX+ rAAV9.
DSS-Nter-amiR-shn3. Seven weeks after the injection, mice were subcutaneously
injected with calcein and alizarin-3-methyliminodiacetic acid at 6-day intervals for
dynamic histomorphometric analysis. Nonlabeled mice were used to monitor
EGFP expression using the IVIS-100 optical imaging or frozen-sections.
Statistical methods. All data were presented as the mean ± s.e.m. Sample sizes
were calculated on the assumption that a 30% difference in the parameters mea-
sured would be considered biologically signiﬁcant with an estimate of sigma of
10–20% of the expected mean. Alpha and Beta were set to the standard values of
0.05 and 0.8, respectively. No animals or samples were excluded from analysis, and
animals were randomized to treatment versus control groups, where applicable. For
relavant data analysis, where relevant, we ﬁrst performed the Shapiro–Wilk nor-
mality test for checking normal distributions of the groups. If normality tests
passed, two-tailed, unpaired Student’s t-test and if normality tests failed, and
Mann–Whitney tests were used for the comparisons between two groups. For the
comparisons of three or four groups, we used one-way ANOVA if normality tests
passed, followed by Tukey’s multiple comparison test for all pairs of groups. If
normality tests failed, Kruskal–Wallis test was performed and was followed by
Dunn’s multiple comparison test. The GraphPad PRISM software (v6.0a, La Jolla,
CA) was used for statistical analysis. P < 0.05 was considered statistically sig-
niﬁcant. *P < 0.05; **P < 0.01; ***P < 0.001; and ****P < 0.0001.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Data supporting the ﬁndings of this manuscript are available from the corresponding
author upon reasonable request.
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